Rheumatoid Arthritis Pipeline Analysis: 50+ Key Companies Advancing the Future of Rheumatoid Arthritis Therapeutics | DelveInsight

DelveInsight's Rheumatoid Arthritis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Rheumatoid Arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Rheumatoid Arthritis pipeline domain.

Key takeaways from the Rheumatoid Arthritis Clinical Trial Landscape Report
• DelveInsight's Rheumatoid Arthritis pipeline report depicts a robust space with 50+ active players working to develop 58+ pipeline therapies for Rheumatoid Arthritis treatment.
• Key Rheumatoid Arthritis companies such as SynAct Pharma, Lynk Pharmaceuticals, Eli Lilly and Company, DeepCure, IMBiologics, Sonoma Biotherapeutics, Rise Therapeutics, and others.
• Promising Rheumatoid Arthritis pipeline therapies in various stages of development include AP1189, LNK01001, Ocadusertib, IMB 101, DC-9476, and others.

Request a sample and discover the recent advances in Rheumatoid Arthritis treatment drugs at: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Rheumatoid Arthritis?
Rheumatoid Arthritis (RA) is an autoimmune disorder of the joints characterized by inflammatory arthritis as well as extra-articular involvement. It commonly involves multiple joints of both hands with morning stiffness that may last for several hours. The worldwide prevalence of RA is about 0.24%. The annual incidence of RA in the United States and other western nations of northern Europe is about 40 per 100,000 persons.
Rheumatoid arthritis patients contain antibodies to citrullinated proteins. These antibodies are called anti-citrullinated protein antibodies (ACPA). The binding of antibodies to proteins leads to complement activation. The most common clinical presentation of RA is polyarthritis of small joints of hands including proximal interphalangeal (PIP), metacarpophalangeal (MCP) joints and wrist.
RA is diagnosed by examining blood test results, examining the joints and organs, and reviewing x-ray or ultrasound images. Current treatments give most patients good or excellent relief of symptoms and let them keep functioning at, or near, normal levels. DMARDs have greatly improved the pain, swelling, and quality of life for nearly all patients with RA.

Emerging Rheumatoid Arthritis Drug Profiles

AP1189: SynAct Pharma
AP1189 (Resomelagon) is a first-in-class IP-protected biased agonist to the melanocortin type 1 (MCr1) and type 3 (MCr3) receptors. The MC1r and MC3r are present on key cells in the immune system, including neutrophils and macrophages. When the AP1189 compound activates the receptors, associated anti-inflammatory and pro-resolving effects are stimulated. The compound thereby reduces ongoing inflammation and promotes endogenous pathways that facilitate resolution. The drug is currently undergoing Phase II clinical trials.

LNK01001: Lynk Pharmaceuticals
LNK01001 is an oral small molecule therapy being developed by Lynk Pharmaceuticals for the treatment of Rheumatoid Arthritis. The therapy is currently in Phase III clinical development and is being evaluated for patients with moderate to severe active Rheumatoid Arthritis.

Learn more about the novel and emerging Rheumatoid Arthritis pipeline therapies at: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Rheumatoid Arthritis Clinical Trial Landscape
• In January 2026, Lynk Pharmaceuticals Co., Ltd. announced positive topline results from its Phase III clinical trial evaluating zemprocitinib (LNK01001) in patients with moderate to severe active rheumatoid arthritis (RA). The study met its primary and key secondary efficacy endpoints, demonstrating statistically significant improvements versus placebo (P < 0.0001), with a favorable safety and tolerability profile.
• In February 2026, SynAct Pharma announced that the company successfully reached the recruitment goal of 240 randomized subjects in the 12-week Phase IIb ADVANCE study of resomelagon in newly diagnosed patients with Rheumatoid Arthritis (RA).
• In November 2025, SynAct Pharma AB announced that the company has randomized 190 out of 240 patients and is on-track on lead program Phase IIb ADVANCE study.
• In January 2025, Rise Therapeutics announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.
• In August 2024, DeepCure announced a collaboration with Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM) to investigate DC-9476 as a potential treatment for Rheumatoid Arthritis patients who do not respond well to current standard of care.

Scope of the Rheumatoid Arthritis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous, Topical
• Therapeutics Assessment By Molecule Type: Small molecule, Monoclonal antibody, Cell therapy, Gene therapy, Protein
• Key Rheumatoid Arthritis Companies: SynAct Pharma, Lynk Pharmaceuticals, Eli Lilly and Company, DeepCure, IMBiologics, and others
• Key Rheumatoid Arthritis Pipeline Therapies: AP1189, LNK01001, Ocadusertib, IMB 101, DC-9476, and others

Dive deep into rich insights for new drugs for Rheumatoid Arthritis treatment, visit at: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Rheumatoid Arthritis Pipeline Report Introduction
2. Rheumatoid Arthritis Pipeline Report Executive Summary
3. Rheumatoid Arthritis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Pipeline: Late Stage Products (Phase III)
7. Rheumatoid Arthritis Pipeline: Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Pipeline: Early Stage Products (Phase I/II)
9. Rheumatoid Arthritis Pipeline Therapeutics Assessment
10. Inactive Products in the Rheumatoid Arthritis Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Rheumatoid Arthritis Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.